Guest guest Posted July 29, 2004 Report Share Posted July 29, 2004 > 29 Jul 2004 03:49:35 -0000 > Ban Plant-based Transgenic Pharmaceuticals > press-release > > > The Institute of Science in Society Science Society > Sustainability http://www.i-sis.org.uk > > General Enquiries sam Website/Mailing > List > press-release ISIS Director > m.w.ho > ======================================================== > > > ISIS Press Release 29/07/04 > > Ban Plant-based Transgenic Pharmaceuticals > ****************************************** > > Prof. Joe Cummins and Dr. Mae-Wan Ho call for a > global forum > and a ban on testing pharm crops, especially in > Third World > countries > > Sources for this report are available in the ISIS > members > site > http://www.i-sis.org.uk/full/BanpharmcropsFull.php. > Full details here > http://www.i-sis.org.uk/membership.php > > As one after another biotech giant retreated from > genetically modified (GM) crops for food and feed in > Europe > (see " Biotech investment busy going nowhere " , this > issue), > the industry is redoubling its efforts to develop > plant- > based transgenic pharmaceuticals in North America > and > elsewhere. > > In April 2004, California stalled a major attempt to > > introduce GM rice producing human lactoferrin and > lyzozyme > into 10 counties, but efforts to use rice and other > food > crops to produce hazardous pharmaceuticals have > continued > unabated. > > On 12 July, the European Union (EU) announced the > award of > 12 million euros to a network of laboratories in 11 > European > countries plus South Africa to explore the > possibilities of > producing pharmaceuticals grown in genetically > modified > plants. The consortium, " Pharma-Planta " , will use > plants to > produce vaccines and treatments against major > diseases > including AIDS, rabies, diabetes and TB. Human > trials of the > drugs are to begin within the next five years. The > project > is co-ordinated in the UK by Prof. Julian Ma of St. > George's > Medical School London; and John Innes Centre, UK's > top GM > crop research institute is also a member of the > consortium. > > A day later, it was revealed that South Africa, the > only > member of the consortium outside Europe, is to be > the test > site of the first pharm crops. South Africa's > Council for > Scientific and Industrial Research is particularly > interested in potential vaccines against HIV. Philip > Dale, > plant technologist at John Innes Centre in Norwich > and the > project's biosafety co-ordinator, reportedly said > that the > cost of 24-hour surveillance of GM fields in the UK > has made > it expensive to conduct similar trials in Britain. > > The use of Third World countries for testing and > producing > plant-based pharmaceuticals unacceptable both in > Europe and > the United States smacks of colonialism. It also > raises the > spectre of unmonitored and unregulated human > exposures to > the dangerous products. This problem will be > exacerbated as > opposition to pharm crops is growing in the United > States, > and more Third World countries will be targeted for > test > sites and production facilities. ISIS has played a > key role > in exposing the marketing of pharm crop products in > the > United States previously unbeknownst to the public, > via a > gaping loophole in the US regulatory system (see > " Pharm crop > products in US market " , this issue). > > A coalition of consumer and environmental > organizations in > the US issued a call for a moratorium on genetically > > engineered pharm crops on 21 July. They want the > California > state agencies to conduct a rigorous investigation > of the > potential hazards posed by a biotech company's plan > to > produce pharmaceutical drugs from genetically > engineered > rice. > > There is an urgent need for proper international > regulation > on the testing and production of plant-based > pharmaceuticals. The first step may be a wider > discussion of > the drawbacks and dangers of plant-based > pharmaceuticals as > well the " advantages " put forward by proponents in > academe > and corporations. The overlooked dangers of pharm > crops > include pharmaceuticals that are toxic, that could > produce > immune sensitization followed by anaphylaxis, or > oral > tolerance leading to loss of immunity to pathogens; > and > general loss of confidence in the food supply. These > have > been discussed in numerous reviews from the > Institute of > Science in Society. > > The United Nations Food and Agriculture Organization > (FAO) > has run a number of electronic conferences around > " Agricultural Biotechnology for Developing Countries > - an > Electronic Forum " . These moderated discussions have > been > quite productive. It is time to have an electronic > forum on > " Plant-based Pharmaceuticals in Developing > Countries " . > > Do contact the administrator of the FAO project Dr. > John > Ruane, at biotech-admin to call for such a > forum as > a matter of urgency. The FAO forums are described at > the > following URL: > http://www.fao.org/DOCREP/004/Y2729E/Y2729E00.HTM > > It is important that the testing and production of > plant- > based pharmaceutical in the Third World are made > public > before they are quietly and extensively carried out > without > the informed consent of those directly affected. > > Meanwhile, it is imperative to impose a ban on field > test > releases and biopharmaceutical production by > multinational > corporations and foundations, especially in Third > World > countries. > > > > ======================================================== > > This article can be found on the I-SIS website at > http://www.i-sis.org.uk/ > > If you like this original article from the Institute > of > Science in Society, and would like to continue > receiving > articles of this calibre, please consider making a > donation > or purchase on our website > > http://www.i-sis.org.uk/donations. > > ISIS is an independent, not-for-profit organisation > dedicated to providing critical public information > on > cutting edge science, and to promoting social > accountability > and ecological sustainability in science. > > If you would prefer to receive future mailings as > HTML > please let us know. If you would like to be removed > from our > mailing list at > > http://www.i-sis.org.uk/mailinglist/.php > ======================================================== > > CONTACT DETAILS > > The Institute of Science in Society, PO Box 32097, > London > NW1 OXR > > telephone: [44 20 8643 0681] [44 20 7383 3376] > [44 20 > 7272 5636] > > General Enquiries sam Website/Mailing > List > press-release ISIS Director > m.w.ho > > MATERIAL IN THIS EMAIL MAY BE REPRODUCED IN ANY FORM > WITHOUT > PERMISSION, ON CONDITION THAT IT IS ACCREDITED > ACCORDINGLY > AND CONTAINS A LINK TO http://www.i-sis.org.uk/ > > Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.